

FOR IMMEDIATE RELEASE

AMNEAL RECEIVES FDA APPROVAL FOR ITS SECOND LIQUID RX PRODUCT, PREDNISOLONE SODIUM PHOSPHATE, USP

Hauppauge, NY (USA), May 4, 2009 – Amneal Pharmaceuticals is pleased to announce that it has received US FDA approval to manufacture Prednisolone Sodium Phosphate Oral Solution in 15 mg/5 mL strength, effective March 10, 2009. This prednisolone oral solution is Amneal's second liquid ANDA, and it is an AA-rated, therapeutically equivalent alternative to Orapred® (a trademark of Ascent Pediatrics, Inc.).

Amneal will sell Prednisolone Sodium Phosphate Oral Solution in two sizes—237 ml (8 oz) and 473 ml (16 oz)—making it the only 16 oz prednisolone solution available on the market. This pale yellow, grape-flavored solution does not require refrigeration.

Prednisolone sodium phosphate is indicated in the treatment of endocrine disorders, rheumatic disorders, dermatologic diseases, allergic states, ophthalmic diseases, respiratory diseases, hematological disorders, neoplastic diseases, edematous state, gastrointestinal disease and nervous system disorders. Amneal began shipping both sizes of Prednisolone Sodium Phosphate Oral Solution in the 15 mg/5 mL strength as of April 28, 2009 and will have the product available through wholesalers-distributors as well as directly to the trade.

This approval marks the second liquid dosage form ANDA filed and approved from Amneal's Branchburg, New Jersey sterile manufacturing plant, which was acquired in December 2007. From the high quality, well-equipped R&D labs at this facility, Amneal has built a strong pipeline of products—both filed and under development—in a variety of dosage forms including liquids, nasal sprays and injectables. The production capacity of the Branchburg plant is well over seven million units per year.

Amneal Pharmaceuticals LLC, headquartered in Paterson, NJ, is a USA-based firm that develops, manufactures and distributes generic pharmaceutical products regulated and approved by the US FDA. Positioned as "Generic's New Generation," the company utilizes diverse R&D and manufacturing expertise to conceive breakthrough developments with lasting impact. Vigorous ANDA growth and broad product acquisitions are key features of Amneal's strategic growth plan, as is the company's commitment to building deep relationships with its customer base. Amneal delivers superior service levels, quality products, and dynamic value throughout the pharmaceutical industry.

###

CONTACT: Jim Luce, Executive Vice President-Sales & Marketing
Amneal Pharmaceuticals, LLC
Direct: 949-610-8018
Mobile: 949-633-2293
Fax: 949-610-8218
E-mail: jim@amneal.com
www.amneal.com
Corporate Headquarters
85 Adams Avenue
Hauppauge, NY 11788